Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Investigation of Cerebral Autosomal Dominant Arteriopathy with Sub-cortical Infarcts and Leukoencephalopathy (CADASIL) using induced pluripotent stem cell modelling and targeted therapeutic research

Project description

Advancing targeted therapies against rare brain disease

Cerebral autosomal dominant arteriopathy with sub-cortical infarcts and leukoencephalopathy (CADASIL) is a rare, hereditary neurological disorder characterised by mutations in the NOTCH3 gene, leading to the accumulation of abnormal proteins in small blood vessels in the brain. This condition can result in a range of symptoms, including recurrent strokes and cognitive decline. Funded by the Marie Skłodowska-Curie Actions programme, the CADASIL-iMATTR project focuses on the increased inflammation and vascular fibrosis associated with CADASIL. Researchers will develop disease models and investigate the implicated pathways. Moreover, they will explore the anti-inflammatory and anti-fibrotic potential of novel lipoxin mimetics as a treatment strategy.

Objective

CADASIL, a rare disease of the small blood vessels, is caused by mutations in NOTCH3 and can cause cognitive decline leading to dementia. Vascular disease is the second most common cause of dementia with the burden set to increase with population aging. Insights into CADASIL will prove instrumental in understanding and treating the vascular contributions to cognitive impairment and dementia (VCID). There are no therapies for CADASIL and a lack of translational human models for identification of dysfunctional pathways/targets and screening of existing and novel therapeutics.
Recent proteomic insights generated at the Elahi Lab show that leukocyte extravasation, vascular fibrosis and inflammatory processes are upregulated in CADASIL. This project will investigate the anti-inflammatory and anti-fibrotic effects of novel pro-resolving synthetic lipoxin mimetics (sLXms). The objectives are to investigate: (1) which cell types and pathways in the vasculature are affected in CADASIL through the use of patient-derived iPSC unicellular and multicellular vascular models; (2) which immune cell types are dysfunctional in CADASIL through immunophenotyping of patient leukocytes and assessment of immunovascular interactions; (3) can sLXms resolve these dysfunctional phenotypes through the use of patient derived-iPSC models and a Zebrafish model of CADASIL. I will work with Asst Prof Elahi, Mount Sinai, a leader in the field of VCID, during the global outgoing phase including a secondment to the Zhang Lab (Harvard). The effects of sLXms in vivo will be explored in the return phase at the Godson Lab at UCD.
This interdisciplinary proposal will merge my immunotherapeutic skillset with expertise of my mentorship team and cutting-edge technologies across several disciplines (iPSC modelling, bioengineering and therapeutics) and will result in impactful discoveries for CADASIL while generating significant European economic development and strengthening transatlantic research networks.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-GF - HORIZON TMA MSCA Postdoctoral Fellowships - Global Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2022-PF-01

See all projects funded under this call

Coordinator

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Net EU contribution
€ 278 571,36
Address
BELFIELD
4 Dublin
Ireland
Region
Ireland Eastern and Midland Dublin
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (2)